QTORIN Rapamycin Gel for Microcystic Lymphatic Malformations

Already resolved: Palvella announced positive topline Phase 3 SELVA results Feb 24, 2026. Primary endpoint met with mean +2.13 mLM-IGA improvement (p<0.001), all secondary endpoints also significant. 95% of evaluable participants improved; well-tolerated. NDA planned 2H 2026. Outcome is clearly positive.

Phase 3 design and a 24-week lesion improvement IGA endpoint support a moderate chance of success, with topical rapamycin mechanistically plausible in vascular malformations. Risk remains from rare heterogeneous lesions, subjective investigator scoring, and post-primary-completion disclosure uncertainty.

Phase 3 status and completed recruitment support feasibility, and a 24-week investigator global assessment can capture visible lesion improvement. But mLM is rare/heterogeneous, endpoint subjectivity and variable lesion burden add noise, with no prior efficacy data shown in fields and some disclosure risk after primary completion.

Phase 3 trial of topical rapamycin gel (known activity in lymphatic/vascular malformations) with single primary mLM-IGA endpoint at Week 24; active not recruiting status after Jan 2026 estimated completion indicates mature data and typical Ph3 success odds for this mechanism in rare disease.

Phase 3, active-not-recruiting, topical mTOR inhibitor in rare disease; standard IGA primary at Week 24; completion date passed 127 days with no termination suggests operational execution on track but limited prior data and subjective endpoint add uncertainty.

Palvella Therapeutics announced positive topline results for the Phase 3 SELVA trial on Feb 24, 2026. The trial met its primary endpoint with a statistically significant improvement (p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) at Week 24. With clear disclosure of positive primary endpoint data, this will definitively resolve YES.

Palvella Therapeutics reported positive topline data from the Phase 3 SELVA trial (NCT06239480) on February 24, 2026. The study met its primary endpoint with a statistically significant improvement on the mLM-IGA at 24 weeks (mean change +2.13, p<0.001). Given this explicit public confirmation of success on the primary endpoint, the resolution is effectively certain.

Phase 3 trial of topical rapamycin for microcystic lymphatic malformations. No prior Phase 2 data available. Rare disease, single pivotal study; base rate for Phase 3 success ~50-60%. Endpoint is IGA, subjective but standard. Without efficacy data, probability near even.

Phase 2 data showed 100% responder rate on mLM-IGA vs 0% placebo, strongly supporting mTOR inhibition in microcystic lymphatic malformations. The Phase 3 uses the same endpoint at 24 weeks, similar population. However, the trial completed primary endpoint collection 4 months ago without topline release, adding uncertainty. Still, intrinsic success odds are high given prior efficacy and unmet need.

Topical rapamycin has strong mechanistic rationale for lymphatic malformations via mTOR inhibition. Phase 3 advancement implies supportive Phase 2 data. IGA endpoint at 24 weeks is reasonable for lesion improvement. Rare disease with high unmet need favors regulatory flexibility. Risk: IGA subjectivity, small sample size typical of rare disease trials, and no posted results 128 days past primary completion.

Topical rapamycin has strong mechanistic and early clinical support for microcystic LM. Sponsor-designed IGA endpoint favors treatment differentiation. Trial is past primary completion, indicating data collection is finished and topline is imminent. Moderate risk of placebo response on IGA, but high overall success probability.

QTORIN (rapamycin gel) has strong mechanistic rationale and positive Phase 2 data in lymphatic malformations. The mLM-IGA endpoint is standard. Palvella has demonstrated clinical proof-of-concept, increasing likelihood of Phase 3 success despite inherent late-stage risks.

Topical rapamycin has strong mechanistic rationale and positive Phase 2 data. The mLM-IGA endpoint is clinically meaningful but subjective. With primary completion passed by months, data is likely finalized. Phase 3 attrition and niche population size moderate success odds, but MoA and prior signals support a favorable outcome.

Phase 3, active‑not‑recruiting trial with a clear, clinically meaningful mLM‑IGA endpoint. Rapamycin gel showed promising Phase 2 efficacy in a rare disease with few alternatives, suggesting a moderate chance of success, but limited data and operational risks keep the probability around 60%.

Phase 3, active‑not‑recruiting trial has already reached primary completion, indicating data collection is done. Rapamycin gel has mechanistic rationale for lymphatic malformations and prior early‑phase signals, but the primary endpoint is a subjective investigator global assessment, which can be variable. No disclosed prior Phase 3 results increase uncertainty, leading to a modest positive outlook around 60%.

Phase 3 topical rapamycin for microcystic lymphatic malformations. Primary completion was 128 days ago (Jan 2026) with no result disclosed yet—suggesting potential data issues or regulatory review complexity. Topical delivery to deep microcystic lesions is mechanistically challenging; prior Phase 2 data showed signals but modest effect sizes. IGA endpoint is subjective and susceptible to placebo response. Extended delay raises disclosure risk. Sponsor is small-cap (PVLA) with limited resources, increasing execution risk. Overall probability below market price.

Phase 3 topical rapamycin for microcystic lymphatic malformations. Primary completion was 127 days ago (Jan 2026) with no results disclosed yet—concerning delay suggesting potential issues. Topical delivery to deep microcystic lesions is mechanistically challenging; rapamycin's poor skin penetration limits efficacy. Prior Phase 2 data was modest. IGA endpoint is subjective and susceptible to placebo response. No recruiting status implies data lock/CSR preparation but extended silence increases downside risk.

Phase 3 pivotal trial for rare disease with clinical endpoint (mLM-IGA). No interim data or prior Phase 2 results provided. Completion date passed suggests data may be maturing. Standard Phase 3 dermatology success rates ~50-60%. Endpoint appears measurable and clinically relevant. No red flags in design, but limited visibility into execution or prior signal.

Phase 3 for rare mLM with topical rapamycin has biological rationale and positive prior signal. However, investigator-assessed endpoint introduces subjectivity risk. Trial past primary completion suggesting near-complete data. Intrinsic edge modest given rare disease complexity and novel gel formulation. Estimate ~55% vs 62% market price.